Atrophic vaginitis, commonly known as vaginal atrophy, is a condition caused by reduced levels of estrogen in the body after menopause. It causes vaginal dryness, itching, burning sensation during sex, and in some cases bleeding. Treatments such as vaginal lubricants and moisturizers, topical estrogen therapies such as creams and rings are used to treat symptoms associated with this condition. The global Atrophic Vaginitis Treatment Market is estimated to be valued at US$ 658.33 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend propelling the growth of the atrophic vaginitis treatment market is increasing oestrogen deficiency among women post-menopause. Around 30-50% of menopausal women suffer from oestrogen deficiency caused vaginal atrophy leading to painful intercourse and urinary issues. With advancing age, the levels of oestrogen in a woman’s body start declining which causes thinning, drying, and inflammation of the vaginal walls. This leads to symptoms of vaginal dryness, irritation, pain or burning sensation during sexual intercourse. The lack of oestrogen also reduces lubrication making sex uncomfortable. The rising awareness about treatments availability and post-menopause healthcare is driving more women to seek medical help for managing vaginal atrophy symptoms.
SWOT Analysis
Strength: Estrogen replacement therapy helps in reducing symptoms and improving quality of life. It also helps reduce risk of other health issues associated with symptoms of atrophic vaginitis.
Weakness: Long term treatment is required which can lead to poor compliance. Cost associated with treatment can also be prohibitive for some patients.
Opportunity: Growing geriatric female population prone to atrophic vaginitis presents large market opportunity. Increasing awareness about management and treatment options also presents an opportunity for market growth.
Threats: Alternative OTC treatments and home remedies can affect prescription drug demand and revenue. Side effects associated with drugs also pose a threat to treatment adherence.
Key Takeaways
The global Atrophic Vaginitis Treatment market is expected to witness high growth over the forecast period. The North America region currently dominates the market owing to well developed healthcare infrastructure and high awareness levels regarding women’s health issues. The Asia Pacific region is expected to grow at a fastest pace due to growing female geriatric population, increasing accessibility to healthcare services and rising disposable incomes.
Key players operating in the atrophic vaginitis treatment market include Pfizer Inc., TherapeuticsMD Inc., Allergan plc (AbbVie Inc.), Duchesnay USA, Novo Nordisk A/S, Merck & Co., Inc., Endoceutics Inc., Bausch Health Companies Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd. These players are focusing on developing advanced treatment options to expand market share and meet the growing need for effective management of atrophic vaginitis.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.